Cantargia (7V3) Stock Overview

A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. More details

7V3 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 98.7% below our estimate of its fair value

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 67.4% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the German market

Does not have a meaningful market cap (€35M)

7V3 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW438,812 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

438,812 investors already sharing narratives

View all narratives

Cantargia AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cantargia
Historical stock prices
Current Share Price	SEK 0.11
52 Week High	SEK 0.56
52 Week Low	SEK 0.11
Beta	1.59
1 Month Change	-16.17%
3 Month Change	-30.77%
1 Year Change	-48.63%
3 Year Change	-63.07%
5 Year Change	-95.11%
Change since IPO	-92.84%

Recent updates

Shareholder Returns

	7V3	DE Biotechs	DE Market
7D	-14.4%	-3.5%	-2.1%
1Y	-48.6%	-8.6%	3.6%

Return vs Industry: 7V3 underperformed the German Biotechs industry which returned -8.6% over the past year.

Return vs Market: 7V3 underperformed the German Market which returned 3.6% over the past year.

Price Volatility

Is 7V3's price volatile compared to industry and market?
7V3 volatility
7V3 Average Weekly Movement	18.0%
Biotechs Industry Average Movement	5.5%
Market Average Movement	5.1%
10% most volatile stocks in DE Market	12.6%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: 7V3's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7V3's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2009	22	Hilde Steineger	cantargia.com

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.

Cantargia AB (publ) Fundamentals Summary

How do Cantargia's earnings and revenue compare to its market cap?
7V3 fundamental statistics
Market cap	€35.04m
Earnings (TTM)	€14.87m
Revenue (TTM)	€28.20m

2.4x

P/E Ratio

1.2x

P/S Ratio

Is 7V3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7V3 income statement (TTM)
Revenue	SEK 317.31m
Cost of Revenue	SEK 0
Gross Profit	SEK 317.31m
Other Expenses	SEK 149.92m
Earnings	SEK 167.38m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Nov 25, 2026

Earnings per share (EPS)	0.67
Gross Margin	100.00%
Net Profit Margin	52.75%
Debt/Equity Ratio	0%

How did 7V3 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/11 01:49
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cantargia AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Arvid Necander	Carnegie Investment Bank AB
Soo Romanoff	Edison Investment Research
Sara Nik	H.C. Wainwright & Co.

Cantargia (7V3) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Cantargia AB (publ) Competitors

2invest

Novogenia

CapForce

Actinium Pharmaceuticals

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

New major risk - Share price stability

Cantargia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 74.999999 million.

Cantargia AB (publ) Announces Start Of New Investigator-Initiated Lung Cancer Prevention Study

Cantargia AB Reports Early Clinical Data And Expands Nadunolimab Development In MDS And AML

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 124.305827 million.

Recent updates

New major risk - Revenue and earnings growth

New major risk - Share price stability

Cantargia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 74.999999 million.

Cantargia AB (publ) Announces Start Of New Investigator-Initiated Lung Cancer Prevention Study

Cantargia AB Reports Early Clinical Data And Expands Nadunolimab Development In MDS And AML

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 124.305827 million.

Cantargia AB (publ) to Report Fiscal Year 2026 Results on Feb 24, 2027

Cantargia AB (Publ) Reports First Patient Dosed in New US Investor-Initiated Colorectal Cancer Study

Cantargia AB (publ) to Report Nine Months, 2026 Results on Nov 25, 2026

Cantargia AB (publ), Annual General Meeting, May 21, 2026

Cantargia AB Announces Executive Changes

Cantargia AB (publ) to Report Q1, 2026 Results on May 19, 2026

Cantargia AB (publ) Appoints Jenny Sundqvist as Board Member

Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneous Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 Pharmacokinetic Model

Cantargia AB (publ) Announces Chief Medical Officer Changes

Cantargia AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026

Cantargia AB (publ) Announces CEO Changes

Cantargia AB (publ) Publishes Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer

Cantargia AB (publ) Expands CAN10 Phase 1 Clinical Program Building on Positive Results

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10